Sam Samad - 12 May 2026 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Reporting relationship: Director
Issuer ticker: IDXX
Reported as of: 12 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 May 2026, 17:00:55 UTC
Prior SEC filing: 24 Apr 2026
Source filing: View source filing
Reporting owner signature: /s/ Lily J. Lu, Attorney-in-Fact for Sam Samad

Key filing fact

Sam Samad filed Form 4 for IDEXX LABORATORIES INC /DE (IDXX) on 14 May 2026.

Key facts

This page summarizes Sam Samad's Form 4 filing for IDEXX LABORATORIES INC /DE (IDXX).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 14 May 2026, 17:00.

Change

Previous filing in this sequence was filed on 24 Apr 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001694295 Primary reporting owner

SAMAD SAM

Relationship: Director
Address: ONE IDEXX DRIVE, WESTBROOK
Signature: /s/ Lily J. Lu, Attorney-in-Fact for Sam Samad
Signature date: 14 May 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IDXX transaction Derivative

Non-Qualified Stock Option (right-to-buy)

Award

Transaction value
Shares: +525
Change %
Price: $0.000000^*
Shares after: 525
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 525
Exercise price: $533.92
Footnotes: F1

IDXX transaction Derivative

Deferred Stock Unit

Award

Transaction value
Shares: +234
Change %: +21%
Price: $0.000000^*
Shares after: 1,354
Date: 12 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 234
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of option to buy shares of Issuer common stock that vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier.

Footnote F2

Each deferred stock unit represents a contingent right to receive one share of Issuer common stock. These deferred stock units vest in one installment on the one year anniversary of the date of grant or on the date of the 2027 annual meeting of shareholders, whichever event is earlier, and by default are payable as common stock as soon as practicable following the date of the Director's resignation from the Board of Directors.